Abstract: Agricultural biotechnology presents opportunities for reducing poverty, food insecurity, child malnutrition, and natural resource degradation. Small farmers in developing countries are faced with many problems and constraints which biotechnology may assist. About 1.2 billion people, or one of every five humans, live in a state of absolute poverty, on the equivalent of US$1 a day or less. Modern biotechnology is not a silver bullet for achieving food security, but, used in conjunction with traditional knowledge and conventional agricultural research methods, it may be a powerful tool. Policies must expand and guide research and technology development to solve problems of importance to poor people. Research should focus on crops relevant to small farmers and poor consumers in developing countries, such as bananas, cassava, yams, sweet potatoes, rice, maize, wheat, and millet, along with livestock. Labelling may also be needed to identify content for cultural and religious reasons or simply because consumers want to know about the contents of their food and the processes used to produce it. It is also urgent that global biosafety standards and local regulatory capacity be strengthened within developing countries.
Introduction
The current debate about the potential utility of modern biotechnology for food and agriculture and the associated potential risks and opportunities is focused on the initial applications of such biotechnology in industrialized country agriculture. The potential contributions of biotechnology to poverty alleviation and enhanced food security and nutrition in developing countries has received little attention beyond blanket statements of support or opposition. Such statements often ignore the differences between the conditions of farmers and consumers in the industrialized world and those of poor farmers and consumers in the developing world. This article attempts to provide input into a more focused debate on the role of modern agricultural biotechnology in developing countries, a debate that should be led by developing countries themselves.
Current food insecurity problems
Small farmers in developing countries are faced with many problems and constraints. Pre-and post-harvest crop losses due to pests and droughts result in low and fluctuating yields, incomes, and food availability. Low soil fertility and lack of access to reasonably priced plant nutrients, along with acid, salinated, and waterlogged soils and other abiotic factors also contribute to low yields, production risks, and degradation of natural resources. Too often, poor farmers must clear forest or farm ever more marginal land in order to cultivate crops. Many rural poor people live in resource poor areas. Inadequate infrastructure and poorly functioning markets, together with lack of access to credit and technical assistance, add to the impediments. About 1.2 billion people, or one of every five humans, live in a state of absolute poverty, on the equivalent of US$1 a day or less [1] . Around 800 million people in the developing world are food insecure ( Figure 1 ) [2] . Of particular concern are the 167 million preschool children who suffer from energy-protein malnutrition ( Figure 2 ) [3] . Also, a very large segment of humanity suffers from deficiencies of micronutrients such as iron and vitamin A. Two billion people (one in every three) are anaemic, usually as a result of inadequate iron in their diets (Figure 3 ), and half a million children go blind each year because of vitamin-A deficiency [3, 4] . Food insecurity and malnutrition result in needless child deaths, serious public health problems, and lost human potential in the developing countries. Source: [3] Around 70% of poor and food-insecure people reside in rural areas and depend directly or indirectly on agriculture for their livelihoods [5] . Whether in rural or urban areas, poor people spend as much as 50-70% of their incomes on food [6] . Low productivity in agriculture is a major cause of poverty, food insecurity, and poor nutrition in low-income developing countries, resulting in low incomes for farmers and farm workers, little demand for goods and services produced by poor non-agricultural rural households, and urban unemployment and underemployment [7] . Productivity gains are also essential to assure that food supplies remain adequate as world population increases by 25% to 7.5 billion in 2020. Over 97% of the projected growth will take place in the developing countries (Table 1 ) [8] . 
Public investment in agricultural development
In low-income developing countries, agriculture is the driving force for broad-based economic growth and poverty alleviation. A healthy agricultural economy also offers farmers incentives for sound management of natural resources. Accelerated public investments are needed to facilitate agricultural and rural growth through:
1 Environmentally friendly, yield increasing crop varieties, including drought-and salt-tolerant and pest-resistant varieties, and improved livestock;
2 Access to appropriate inputs and credit;
3 Extension services and technical assistance;
4 Improved rural infrastructure and effective markets;
5 Attention to the needs of women farmers, who grow much of the locally produced food in many developing countries; and 6 Primary education and health care, clean water, safe sanitation, and good nutrition for all.
These investments must be supported by good governance and an enabling policy environment. Also, agricultural and rural development efforts must engage poor people as active participants, not passive recipients. This means reversing current trends. Public investment in agriculture is on the decline in developing countries, which on average devote 7.5% of government spending to agriculture (and just 7% in Sub-Saharan Africa) [9] . Aid donors cut assistance to agriculture and rural development by nearly 50% in real terms over 1986-1996. Donors' rather inflexible emphasis of the past 20 years on less government and a smaller public sector has contributed to public disinvestment in agriculture [9] [10] [11] .
Public investment in agricultural research that can improve the productivity of small farmers in developing countries is especially important. It must join all appropriate scientific tools with better utilization of the insights of traditional indigenous knowledge. The private sector is unlikely to devote substantial resources to this area because it cannot expect sufficient returns to cover costs. Even minor increases in aid to agricultural research for developing countries can significantly boost food supplies, while relatively small cuts can have very serious negative effects. Globally, average annual returns to investment in agricultural research and development range from 45 to 79% [12, 13] . Yet, low-income developing countries invest less than 0.5% of the value of farm production in agricultural research, compared to 2% in higher-income countries ( Figure 4 ) [14] . Source: [14] 4 The role of agricultural biotechnology in achieving food security Although tissue culture and other biotechnological work is underway in several developing countries, very little transgenic seed material has been grown in the developing world, and a few countries -Argentina, Brazil, China, Egypt, India, and South Africa -account for almost all of the current research. Hence, ex post assessment of its risks and benefits, and of its relevance for the problems outlined above, is virtually impossible. However, a great deal is known about the social and economic risks and benefits associated with conventional Mendelian plantbreeding. Therefore, we begin our analysis with identification of similarities and differences between conventional breeding and modern biotechnology to help assess ex ante the likely risks and benefits of the latter.
Comparing conventional breeding and modern biotechnology
Within-species vs. transgenic breeding. There are four major relevant differences between conventional plantbreeding and modern biotechnology. First, and most obviously, much current work in agricultural biotechnology involves the transfer of a single or a few genes between species and even from micro-organisms and animals to plants. While all plantbreeding arguably involves 'genetic modification,' conventional breeding crosses different varieties within a single species. There is considerable debate about whether gene transfers across traditional species boundaries entail significant risks to human health and the environment. There is, however, no evidence that there are any social and economic risks inherent in the technology.
A shift to private sector research. Second, it is the public sector that has traditionally taken the lead in conventional crop research, especially in the developing countries. As a direct consequence, improved seed was usually freely available for multiplication and distribution. In other instances, the improved material was subjected to breeders' rights, which may permit an initial charge, but even in these instances, intellectual property rights did not extend beyond the initial release. Having acquired the seed, farmers could reuse it without further payment, although reuse of hybrid seed would drastically reduce the yield advantage. Such practices are in keeping with the principle of 'farmers' rights' that is included in the International Undertaking on Plant Genetic Resources. Negotiations are currently underway to incorporate this agreement into the Convention on Biological Diversity as a legally binding protocol [15, 16] .
In contrast, the bulk of modern agricultural biotechnology research is undertaken by private sector firms, which protect intellectual property rights through patents that extend beyond the first release. Thus, farmers cannot legally plant or sell for planting the crop produced with the patented seed without the permission of the patent holder. Patent holders are currently seeking to enforce their intellectual property rights through legal agreements and technologies that will deactivate specific genes.
The use of legal instruments is widespread for industrialized country agriculture, but does not at present appear viable for poor developing countries. Monitoring and enforcing contracts that prohibit large numbers of small farmers to use the crops they produce as seed would be expensive and difficult.
The so-called terminator gene is the first patented component of the technological approach to intellectual property protection. Seeds containing this gene produce plants with sterile seeds. This technology is not appropriate for small farmers in developing countries because existing infrastructure and production processes may not be able to keep fertile and infertile seeds apart. Small farmers could face severe consequences if they inadvertently planted infertile seeds.
Rise of proprietary research processes and technologies. A third and related distinction between conventional crop breeding and modern biotechnology relates to the patenting of processes as well as products. Conventional breeding technology lies in the public domain, and has frequently been employed by public institutions. The processes used in modern agricultural biotechnology are increasingly subjected to intellectual property protections, along with the products that result.
This means that public sector research institutions may not be able to gain access to basic but proprietary knowledge and processes needed in research, e.g. research on the so-called orphaned crops, such as cassava and millet. These are critical staples in the diets of many poor people, but they do not offer promising economic returns to private sector research and development efforts, so efforts to develop disease-resistant cassava or drought-tolerant millet, whether through genetic modification or conventional breeding, must come from the public sector. Some firms have agreed to transfer proprietary technologies, without charging royalties, to developing countries where there are few potential commercial prospects. For example, Monsanto has entered into agreements with Kenyan and Mexican government agricultural research institutes on developing virusresistant sweet potatoes and potatoes, respectively. In the Mexican case, the transfer involved a donation of genes and know-how, brokered by the International Service for the Acquisition of Agri-Biotech Applications. But, so far, such arrangements are few and generally involve the philanthropic arms of the private firms [17, 18] .
Enlightened adaptation vs. direct transfer. A final difference involves the adaptation of developed country agricultural research to developing country conditions. Conventional breeding efforts that focused on solving specific problems in developing countries (such as high yielding rice) adapted technology first applied in the developed countries. Most current applications of modern biotechnology focus on developedcountry agriculture.
Industrial country research institutions had begun working on development of higher yielding crop varieties in the late 19th century. Much of this work occurred at public institutions or as a result of public-private partnerships. The results from this research could not simply be transferred to poorer developing countries, where the need was for improved varieties of locally consumed staples. Rather, there was further adaptation to the agroecological conditions of tropical and semi-tropical areas as well as a focus on locally consumed crops, such as rice, root and tuber crops, and tropical fruits and vegetables as well as different strains of maize and wheat from those grown in temperate zones.
The public sector role in this adaptation process was, if anything, even more prominent than in the developed world, with international agricultural research centres and national agricultural research systems (particularly in Asia and Latin America) playing the lead roles. Financial support came from donors of official development assistance and large private foundations, such as Ford, Rockefeller, and Kellogg.
In contrast, modern agricultural biotechnology is still in an early phase, and the focus is overwhelmingly on production on developed country farms and for developed country markets. In 1999, 82% of the land planted to genetically modified (GM) crops was in the USA and Canada, with the USA alone accounting for 72% of the area. Argentina, China, Australia and South Africa cultivated the remaining 18%, and the countries other than China include a substantial number of large-scale, capital-intensive farms that produce primarily for industrialized country markets ( Figure 5 ). Among the crops produced in these three developing countries are insect-resistant cotton and maize, herbicide resistant soybeans, and tomatoes with a long shelf life. Globally, herbicide-resistant soybeans and GM maize account for 82% of all plantings (Table 2 ). Both the area planted to GM crops and the value of the harvests grew dramatically between 1995 and 1999: from less than a million hectares to 39.9 million, and from US$75 million to an estimated US$2.2 billion (Figures 6 and 7 ) [19, 20] . Source: [21] Not only has the private sector played the dominant role in research, but consolidation has proceeded rapidly in the agricultural biotechnology industry, with more than 25 major acquisitions and alliances worth $15 billion between 1996 and 1998. This parallels consolidation elsewhere in the food and agricultural industry, e.g. the 1999 merger of Cargill and Continental Grain, the two largest grain trading companies in the world. So far, neither public programs nor public-private partnerships are the norm in agricultural biotechnology research, although there are significant examples of both.
To date, little private sector agricultural biotechnology research has focused on developing country food crops other than maize. Moreover, little adaptation of the research to developing country crops and conditions has occurred through the 'enlightened' (i.e., not for profit, public goods oriented) public and philanthropic channels prominent in conventional breeding efforts in the developing countries. Except for limited work on rice, maize, and cassava, mostly done by the international agricultural research centres of the Consultative Group on International Agricultural Research (CGIAR), little biotechnology research currently focuses on the productivity and nutrition of poor people. The Rockefeller Foundation's agriculture program is one of the few examples; in 1998, it provided about $7.4 million for biotechnology research relevant to developing countries, mainly through international agricultural research centres and national agricultural research systems in developing countries, with a major emphasis on rice. This sum pales by comparison with Monsanto's 1998 research and development budget of $1.3 billion, much of which funded agricultural biotechnology research [22, 23] .
As with conventional breeding, the challenge is to move from the scientific foundation established by developed country-oriented research efforts to research focused on the needs of poor farmers and consumers in developing countries. Direct transfers of the fruits of agricultural biotechnology research to the developing world are not appropriate. This is particularly the case for currently available technology. For example, poor farmers in developing countries may not be able to afford herbicides. More appropriate research for the developing world might focus on biotechnology and conventional breeding to develop alternative forms of weed resistance. For example, the West African Rice Development Association (WARDA), an international agricultural research centre based in Côte d'Ivoire, used a combination of conventional breeding and tissue culture to cross African and Asian rice varieties. This resulted in a hardy, leafy rice that denies weeds sunlight. In addition to improved yields, this reduces the time women must spend weeding, allowing them to devote more attention to the childcare practices that are essential for good nutrition [24] .
Insect resistant crops could have great potential value for poor farmers. So far, however, the development of crops containing genes from the Bacillus thuringiensis (Bt) bacterium, which produces a natural insecticide, has focused on the crops and cropping environments of North America. Currently available Bt crops require extremely knowledge-intensive cultivation. For example, licences for use of Bt maize in the United States require farmers to plant a 'refuge' of non-Bt maize to prevent rapid development of resistance to Bt in the targeted pests. These crops might well be transferable to largerscale operations in some developing countries such as Argentina. There is considerable debate about associated risks of the development of resistance in pests, harm to beneficial insects, and cross-pollination of wild and weedy relatives. But the evidence on these issues so far is inconclusive.
Research on crops and problems of relevance to small farmers in developing countries, including biotechnology research, will require expanded enlightened adaptation, engaging public and philanthropic institutions, including international agricultural research centres. Additional public resources must be allocated to such efforts. In addition, the public sector can expand private sector research for poor people by converting some of the social benefits to private gains, e.g. by offering to buy exclusive rights to newly developed technology and make it available either for free or for a nominal charge to small farmers. The private research agency would bear the risks, as it does when developing technology for the market. This arrangement is similar to that recently proposed by Harvard University economist Jeffrey Sachs for developing a malaria vaccine for use in Africa [25] . There is no reason to believe that the rates of return to agricultural biotechnology research would be less than those for conventional research.
Without more enlightened adaptation, continued expansion of GM crop production in the developed countries may well have a negative impact on small farmers in developing countries, as imported GM grain and feed crops undercut local production. Some developing-country consumers would benefit, but those consumers who also farm could experience net losses. Also, the development of GM substitutes for developing-country export crops, such as cocoa (which in many developing countries is produced by small farmers) could have a devastating impact on developing-country farmers' livelihoods.
Lessons from conventional breeding. Experience with conventional crop research offers some guideposts for assessing the likely risks and benefits of agricultural biotechnology for developing countries. Risks and benefits may be inherent in a given technology, or they may transcend the technology. The policy environment into which a technology is introduced is critical. For example, IFPRI research has found that in Tamil Nadu state in India, the adoption of high-yielding grain varieties meant not only increased yields and cheaper, more abundant food for consumers, but income gains for small-and larger-scale farmers alike, as well as for non-farm poor rural households. Increased rural incomes contributed to nutrition gains [26] . Because the Tamil Nadu state government has pursued active poverty alleviation strategies, including extensive social safety net programs and investment in agriculture, rural development, nutrition, and education, and a fair measure of equity in access to resources such as land and credit, the benefits were widely shared. Where increased inequality followed the adoption of modern crop varieties, this was not because of factors inherent in the technology, but rather a result of policies that did not promote equitable access to resources and development of human capital. And even in these areas, rural landless labourers usually found new job opportunities as a consequence of increased agricultural productivity, particularly where appropriate physical infrastructure and markets developed.
On the other hand, successful adoption of these crop varieties depended on access to water, fertilizer, and pesticides. Thus, inequality between well endowed and resource poor areas increased because of the properties of the technology itself. Likewise, excessive or improper use of chemical inputs led to adverse environmental impacts in some instances. To some extent, this problem was offset by characteristics that were also inherent in the technology: by allowing yield gains without expanding cultivated area, the technology kept cultivators from clearing forests and marginal lands.
Applications of agricultural biotechnology to developing countries could address some of these very issues if research focuses on how to reduce the need for inputs and increase the efficiency of input use. This could lead to the development of crops that utilize water more efficiently, fix nitrogen from the air, extract phosphate from the soil more effectively, and resist pests without the use of synthetic pesticides. Successful efforts in this direction would reduce dependence on access to inputs, making the technology more readily available to poor farmers.
It is possible that the introduction of agricultural biotechnology into developing countries can contribute to increased productivity, lower unit costs and prices for food, preservation of forests and fragile land, poverty reduction, and improved nutrition. This depends on whether the research is relevant to poor people, on the economic and social policy environment, and on the nature of the intellectual property rights arrangements governing the technology.
Weighing risks and benefits of biotechnology in developing countries
The experience of the industrialized countries. In the industrialized countries, it is generally assumed that the economic benefits of GM crops accrue primarily to the life science companies that develop the new varieties and hold the patents, along with the seed companies that distribute them (increasingly, these firms are often integrated as a consequence of mergers and acquisitions). While farmers stand to gain from reduced pest management costs and greater efficiency of pesticide use (in the case of herbicide tolerant crops), the potential yield gains may mean reduced prices. The assumption is that consumers' gains through reduced prices will be rather modest. There are social and environmental benefits to reduced pesticide use, though these could be offset by environmental and health problems that might occur [27] [28] [29] .
As GM crops have only been commercially available for about five growing seasons, the jury is still out on the economic benefits, especially given consumer resistance in some industrialized countries. However, some recent studies of these crops in the United States suggest that the reality may be more complex than the conventional wisdom indicates. One study found that in 1997, agribusiness gained 44% of the benefits from the US Bt cotton crop, while farmers earned almost as much, 42%. Consumers in the United States and abroad reaped a 13% share. For herbicide-tolerant soybeans, the gains favoured consumers even more (21%), while farmers gained fully half. Agribusiness's share was only 31% (Figure 8 ) [30] . Another soybean study confirms the global consumer gains and those of agribusiness, but suggests that yield gain's price depressing effects may wipe out any benefits farmers could hope to achieve [31] . A study of Bt maize in Indiana found that the price premium placed on Bt seed is so high that the gains from efficiency and reduced pesticide use may not justify the costs, unless farmers face a relatively high probability of European corn-borer infestation and their yields are higher than average [32] . This literature suggests that, even under monopoly or oligopoly ownership of the technology, farmers and consumers may gain from these crops, and the benefits to consumers may be rather larger than generally assumed.
Consumers' own risk/benefit calculation is likely to vary according to how they earn their income and how much of their income they spend on food. Consumers outnumber farmers by a factor of more than 20 in the European Union, and Europeans spend only a tiny fraction of their incomes on food. In the United States, farms account for less than 2% of all households, and the average consumer spends less than 12% of income on food [33] [34] [35] . In the developed countries, consumers can afford to pay more for food, increase subsidies to agriculture, and give up opportunities for better-tasting and better-looking food. In contrast, in developing countries, poor consumers depend heavily on agriculture for their livelihoods and spend the bulk of their income on food. Thus, productivity gains and lower unit costs and prices are critical for them. Other consumers 13.0%
Source: [30] Modern biotechnology is not a silver bullet for achieving food security, but, used in conjunction with traditional knowledge and conventional agricultural research methods, it may be a powerful tool in the fight against poverty that should be made available to poor farmers and consumers. It has the potential to help enhance agricultural productivity in developing countries in a way that further reduces poverty, improves food security and nutrition, and promotes sustainable use of natural resources. Solutions to the problems facing small farmers in developing countries will benefit both farmers and consumers. Strong opposition to GM food in the European Union has resulted in severe restrictions on modern agricultural biotechnology, including a three-year moratorium on approval of commercial use of new GM agricultural products. The opposition is driven in part by perceived lack of consumer benefits, uncertainty about possible negative health and environmental effects, widespread perception that a few large corporations will be the primary beneficiaries, and ethical concerns.
The potential benefits in developing countries. There are many potential benefits for poor people in developing countries. Biotechnology may help achieve the productivity gains needed to feed a growing global population, introduce resistance to pests and diseases without costly purchased inputs, heighten crops' tolerance to adverse weather and soil conditions, improve the nutritional value of some foods, and enhance the durability of products during harvesting or shipping. Bioengineered products may reduce reliance on pesticides, thereby reducing farmers' crop protection costs and benefiting both the environment and public health. Biotechnology research could aid the development of drought-tolerant maize and insect-resistant cassava, to the benefit of small farmers and poor consumers. The development of cereal plants capable of capturing nitrogen from the air could contribute greatly to plant nutrition, helping small farmers who often cannot afford fertilizers. Biotechnology may offer cost-effective solutions to micronutrient malnutrition, such as vitamin A-and iron-rich crops. By raising productivity in food production, agricultural biotechnology could help further reduce the need to cultivate new lands and help conserve biodiversity and protect fragile ecosystems.
Policies must expand and guide research and technology development to solve problems of importance to poor people. Research should focus on crops relevant to small farmers and poor consumers in developing countries, such as bananas, cassava, yams, sweet potatoes, rice, maize, wheat, and millet, along with livestock.
Food safety and biosafety. GM foods are not intrinsically good or bad for human health. Their health effects depend on their specific content. GM foods with a higher-iron content are likely to benefit iron deficient consumers. But the transfer of genes from one species to another may also transfer characteristics that cause allergic reactions. Thus, GM foods need to be tested for allergy transfers before they are commercialized. Such testing avoided the commercialization of soybeans containing a Brazil nut gene. GM foods with possible allergy risks should be fully labelled.
Labelling may also be needed to identify content for cultural and religious reasons or simply because consumers want to know about the contents of their food and the processes used to produce it, so that they can make informed choices. While the public sector must design and enforce standards as well as labelling required to protect public health, other labelling might best be left to the private sector in accordance with consumer demands for knowledge.
Failure to remove antibiotic-resistant marker genes used in research before a GM food is commercialized presents a potential although unproven health risk. Recent legislation in the European Union requires that these genes be removed before a GM food is deemed safe.
Risks and opportunities associated with GM foods should be integrated into the general food safety regulations of a country. In addition, effective national biosafety regulations should be in place before modern biotechnology is introduced. Aid donors need to help developing countries build the capacity to monitor compliance and enforce these kinds of regulations. In addition, there needs to be minimal global standards in place. The development of a public global regulatory capacity has lagged far behind the pace of economic globalization [20] .
The ecological risks policymakers need to assess include the spread of traits such as herbicide resistance from genetically modified plants to unmodified plants (including weeds), the build-up of resistance in insect populations, and the potential threat to biodiversity posed by widespread monoculture of bioengineered crops. These risks are particularly significant in the centres of origin and diversity of major food crops. Applications of technology that can switch specific genetic characteristics off and on offer great promise for the development of a seed that will avoid the spread of new traits through cross-pollination. The seed would contain the desired traits, such as pest resistance or drought tolerance, but these would be activated through chemical treatment. Otherwise, the seed would maintain its normal characteristics. Thus, if a farmer planted an improved seed, the offspring would not be sterile; rather they would revert to normal seeds, without the improved traits. The farmer would have the choice of planting the seed and doing no more, or activating the improved traits by applying the chemical. Contrary to the 'terminator' gene, this approach complies with the principle of doing no harm.
Both food safety and biosafety regulations should reflect international agreements and a given society's acceptable risk levels, including the risks associated with not using biotechnology to achieve desired goals. Poor people should be included directly in the debate and decision-making about technological change, the risks of that change, and the consequences of no or alternative kinds of change.
Thorough testing is necessary to ensure the safety of new crop varieties developed through biotechnology. Questions about environmental safety and health risks must be addressed head-on. Testing of genetically modified crops needs to increase in developing countries; at present, about 90% of the testing occurs in developed countries. Destruction of test plots by anti-GM activists should cease. Open debate about the issues involved is essential, but physical attacks on research and testing efforts contribute little to the free exchange of ideas or the formulation of policies that will advance food security.
Socioeconomic risks. Unless developing countries have policies in place to assure that small farmers have access to extension services, productive resources (such as land, water, and credit), markets, and infrastructure, there is considerable risk that the introduction of agricultural biotechnology could lead to increased inequality of income and wealth, because larger farmers may capture most of the benefits through early adoption of the technology, expanded production, and reduced unit costs [36] .
An ex ante assessment of Monsanto's transfer of transgenic virus resistance technology for potatoes to Mexico examined some of the issues relating to social and economic benefits. It found that all classes of potato growers would likely benefit. Because small farmers have higher yield losses from viruses than larger producers, their yield gains and per-unit cost reductions are likely to exceed those of large farmers. Thus, this assessment found the technology to be biased toward small, rather than large farmers. This bias is reinforced by Monsanto's unwillingness to licence the potato leaf roll virus resistance technology for use with the potato variety that accounts for 69% of large farmers' plantings, because this variety is also grown in industrialized countries. Mexican seed distributors would be unlikely to charge a premium for the transgenic seed, which Monsanto transferred without charging royalties, given the competitive nature of the industry in Mexico. The study also found that a targeted government intervention to make transgenic red potatoes available to small and medium sized farmers, comparable to the government seed distribution program for maize and bean seeds (Alianza para el Campo), would allow small farmers to capture 45% of the economic benefits from the cultivation of transgenic potatoes. Consumers would benefit from lower prices as a result of higher production. However, as Mexico reduces potato import barriers, the consumer gains are likely to decline [18] .
Growing concentration among companies engaged in agricultural biotechnology research may lead to reduced competition, monopoly or oligopoly profits, exploitation of small farmers and consumers, and extraction of special favours from governments. Effective antitrust legislation and enforcement institutions are needed, particularly in small developing countries where one or only a few seed companies operate. As with biosafety, there is an urgent need for global standards regarding industrial concentration.
Developing countries will need to enact and enforce intellectual property rights legislation in order to benefit from biotechnology. This legislation must harmonize protection of farmers' rights to access to germplasm and plant breeders' rights to benefit from their innovations.
Trade-related risks. The outcome of new global agricultural trade negotiations, could also bear upon developing countries' social and economic risks related to biotechnology. If the European Union's 'precautionary principle' is accepted as the basis for new agreements on sanitary and phytosanitary standards and technical barriers to trade, then the EU could discriminate against any potential exporters of GM food or feed without having any scientific evidence of harm. At present, because it is private consumers and retailers that are rejecting GM foods in Europe, the discrimination is not government trade policy and does not violate World Trade Organization rules.
Regardless, low-income developing countries that wish to use an agricultural exportled growth strategy will be faced with the choice between adopting modern biotechnology in agriculture or maintaining the possibility of a GM-free food export to the EU. They could choose to differentiate and label GM foods and non-GM foods, and to the extent that they can manage such a differentiated system, they would be able to capture the benefits from modern agricultural biotechnology for domestic consumption while maintaining an export market for GM-free foods. Developing countries may also decide to label GM foods and GM-free foods in the domestic market to provide the choice to domestic consumers. In view of the tremendous importance of productivity increases in agriculture in low-income developing countries for poor people in both urban and rural areas, it is hard to believe that any low-income developing country would refrain from utilizing appropriate modern biotechnology in agriculture once reasonable biosafety limits have been established.
A large share of the food imported by developing countries originates in the United States and these importing countries must take a position on not only biosafety and food safety, but also whether they wish to insist on product differentiation and labelling in the case of imported food.
Moreover, if public opposition in developed countries leads to moratoria or outright bans on agricultural biotechnology research, developing countries could not expect to receive any scientific or financial support for their own research in this area. In practical terms, this would likely preclude most such research in the developing world, except for research in a few large countries such as China, India, and Brazil.
Ethical issues. A major ethical concern is that genetic engineering and 'life patents' accelerate the reduction of plants, animals, and micro-organisms to mere commercial commodities, bereft of any sacred character. This is far from a trivial consideration. However, all agricultural activities constitute human intervention into natural systems and processes. Continued human survival depends on precisely such interventions, and is likewise a critical ethical concern. Condemning biotechnology for its potential risks without considering the alternative risks of prolonging the human misery caused by hunger, malnutrition, and child death is as unwise and unethical as blindly pursuing this technology without the necessary biosafety.
Conclusion
Expanded enlightened adaptive research on agricultural biotechnology can contribute to food security in developing countries, provided that it focuses on the needs of poor farmers and consumers in those countries, identified in consultation with poor people themselves. Public sector research, particularly through international agricultural research centres and national agricultural research systems, is essential for assuring that molecular biology-based science serves the needs of poor people. Yet at present, public international agricultural research centres are devoting less than 10% of their research budgets to biotechnology. And the possibilities for cooperation between the public and private sectors, such as publicly funded private sector research, have barely been tapped. It is also urgent that global biosafety standards and local regulatory capacity within developing countries be strengthened within developing countries.
Agricultural biotechnology must be viewed as one element in a comprehensive sustainable poverty alleviation strategy focused on broad-based agricultural growth, not a technological quick fix for world hunger. There is considerable potential for biotechnology to contribute to improved yields and reduced risks for poor farmers, as well as more plentiful, affordable, and nutritious food for poor consumers. It is not, as some critics have charged, 'a solution looking for a problem.' The problems are genuine and momentous.
The biggest risk of modern biotechnology for developing countries is that technological development will bypass poor people. A form of what Ismail Serageldin, the Chairman of the CGIAR, calls 'scientific apartheid' may well develop, in which cutting edge science becomes oriented exclusively toward industrial countries and largescale farming [17] . In such a case, or if agricultural biotechnology research is prohibited in the developed countries, opportunities for reducing poverty, food insecurity, child malnutrition, and natural resource degradation will be missed, and the productivity gap between developing and developed country agriculture will widen.
